§ 17-180.1 Overdose prevention and reversal training; needle, syringe, and sharps buyback.
AC § 17-180.1
Editor's note: this section has been amended by L.L. 2026/020, 1/17/2026, eff. 5/17/2026 and L.L. 2026/029, 1/17/2026, eff. 5/17/2026. a. Definitions. For the purposes of this section, the following terms have the following meanings: Opioid. The term "opioid" means an opiate as defined in section 3302 of the public health law. Opioid antagonist. The term "opioid antagonist" means naloxone, narcan or other medication approved by the New York state department of health and the federal food and drug administration that, when administered, negates or neutralizes in whole or in part the pharmacological effects of an opioid in the human body. b. For as long as the department determines there is an urgent public health need, the department shall offer overdose prevention and reversal training to the general public. Such training shall include: 1. How to recognize an opioid overdose; and 2. How to properly administer common opioid antagonists to reverse an opioid overdose. c. For as long as the department determines there is an urgent public health need, the department shall offer a public awareness strategy to inform the public of the existence of such trainings and the danger of opioid addiction and abuse. d. For as long as the department determines there is an urgent public health need, the department shall provide opioid antagonists to all syringe exchange programs operating within the city. e. The department shall require that the staff at all syringe exchange programs operating in the city receive overdose prevention and reversal training. Such training shall teach staff: 1. How to recognize an opioid overdose; and 2. How to properly administer common opioid antagonists to reverse an opioid overdose. f. Thirty days prior to the department's determination that there is no longer an urgent public heath need, pursuant to subdivisions b, c and d of this section, the department shall submit a report to the speaker of the council detailing the reasons for such determination. g.
1.Needle, syringe, and sharps buyback pilot program. The department shall establish a needle, syringe, and sharps buyback pilot program. Such program shall offer financial incentives to individuals who collect and return needles, syringes, and sharps that were used for non-medical consumption. In implementing such program, the department shall establish at least 1 buyback location in each of the 5 highest-need council districts in the city, as determined by the department. The department shall set the amount of the buyback incentive for such program, except that such incentive shall not exceed 20 cents per needle, syringe, or sharp and shall not exceed a maximum payout of $10 per day to any individual. The department shall determine eligibility for such program and may consult with overdose prevention centers, the New York city health and hospitals corporation, or any other entity deemed relevant by the commissioner in administering such program.
2.Implementation. The pilot program shall commence no later than 30 days after the effective date of the local law that added this subdivision and conclude one year after the date such program commences. On or before the date the pilot program commences, the department shall conspicuously post on its website a list of the buyback locations included in the pilot program.
3.Report. No later than six months following the conclusion of the pilot program, the department shall submit to the mayor and the speaker of the council, and post conspicuously on the department's website, a report on the pilot program established pursuant to this subdivision. Such report shall include, at a minimum, the following information: (a) The names and addresses of all buyback locations included in the pilot program; (b) The number of needles, syringes, and sharps returned or disposed of under the pilot program, disaggregated by buyback location; (c) The total amount of money disbursed to individuals; and (d) The department's recommendation as to whether to establish a permanent buyback program and whether and how to expand such program. h.
